Lilly’s New Weight-Loss Pill Foundayo Gets Off to a Slow Start
Lilly’s new weight-loss pill started slow, far behind Novo’s, but it’s too early to tell which drug will win.
Already have an account? Sign in.
Lilly’s new weight-loss pill started slow, far behind Novo’s, but it’s too early to tell which drug will win.
Ascentage Pharma gets Buy ratings; its cancer drugs show strong results, fast growth in China, and high future upside potential.
Investors offered to buy Seer for $2.35/share plus extra future payout; stock rose after takeover bid. Board responds by May 2.
PagerDuty stock jumped as Goldman Sachs raised its stake, sparking rumors that activist investors may push for big changes or a sale.